Browse > Article

Improvement of Dissolution Rate for Zaltoprofen Tablets Using CMC and HPMC  

Park, Hyun-Jin (Department of BIN Fusion Technology & Department of Polymer Nano Science & Technology, Chonbuk National University)
Hong, Hee-Kyung (Department of BIN Fusion Technology & Department of Polymer Nano Science & Technology, Chonbuk National University)
Song, Yi-Seul (Department of BIN Fusion Technology & Department of Polymer Nano Science & Technology, Chonbuk National University)
Hong, Min-Sung (Department of BIN Fusion Technology & Department of Polymer Nano Science & Technology, Chonbuk National University)
Seo, Han-Sol (Department of BIN Fusion Technology & Department of Polymer Nano Science & Technology, Chonbuk National University)
Hong, Dong-Hyun (Department of BIN Fusion Technology & Department of Polymer Nano Science & Technology, Chonbuk National University)
Lee, Dong-Won (Department of BIN Fusion Technology & Department of Polymer Nano Science & Technology, Chonbuk National University)
Khang, Gil-Son (Department of BIN Fusion Technology & Department of Polymer Nano Science & Technology, Chonbuk National University)
Publication Information
Polymer(Korea) / v.34, no.4, 2010 , pp. 300-305 More about this Journal
Abstract
Zaltoprofen is a propionic acid derivative of non-steroidal anti-inflammatory drugs (NSAIDs) and has been widely used in the treatment of a number of arthritic conditions or lumbago. Zaltoprofen has low water solubility and low bioavailability, therefore great efforts have been devoted to enhance the extent of drug adsorption. In this study, zaltoprofen was formulated into a tablet to enhance the bioavailability and to achieve sustained-release using additives such as lactose monohydrate, carboxymethylcellulose (CMC), hydroxypropylmethylcellulose (HPMC). Fourier transform-infrared (FTIR) and differential scanning calorimeter (DSC) were employed to study the structure and crystallization of zaltoprofen in the tablet with various contents of additives. It was found that additives had interactions with zaltoprofen and inhibited the crystallization of zaltoprofen. Tablets containing low viscosity HPMC showed a higher release than those containing high viscosity HPMC. Also, as the amount of CMC increased zaltoprofen release increased.
Keywords
zaltoprofen; dissolution rate; bioavailability; HPMC; CMC;
Citations & Related Records

Times Cited By Web Of Science : 0  (Related Records In Web of Science)
Times Cited By SCOPUS : 1
연도 인용수 순위
  • Reference
1 L. Ribeiro, D. C. Ferreira, and F. J. B. Veiga, J. Control. Release, 103, 325 (2005).   DOI   ScienceOn
2 T. Ishikawa, Y. Watanabe, K. Takayama, H. Endo, and M. Matsumoto, Int. J. Pharm., 202, 173 (2000).   DOI   ScienceOn
3 K. Hirate, A. Uchida, Y. Ogawa, T. Arai, and K. Yoda, Neurosci. Res., 54, 288 (2006).   DOI   ScienceOn
4 G. M. Khan and J. B. Zhu, J. Control. Release, 56, 127 (1998).   DOI   ScienceOn
5 L. M. Harwood, Experimental Organic Chemistry, L. M. Harwood, C. J. Moody, and J. M. Percy, Editors, Blackwell Science Ltd., Oxford, p 683 (1999).
6 V. G. Mir, J. Heinamaki, O. Antikainen, O. B. Revoredo, A. I. Colarte, O. M. Nieto, and J. Yliruusi, Eur. J. Pharm. Biopharm., 69, 964 (2008).   DOI   ScienceOn
7 R. Steendam and C. F. Lerk, Int. J. Pharm., 175, 33 (1998).   DOI   ScienceOn
8 J. H. Kirk, S. E. Dann, and C. G. Blatchford, Int. J. Pharm., 334, 103 (2006).
9 H. B. Tanga. A. Inouea, K. Oshitab, K. Hiratec and Y. Nakataa, Neuropharmacology, 48, 1035 (2005).   DOI   ScienceOn
10 M. Matsumoto, M. Inoue, and H. Ueda, Neurosci. Lett., 397, 249 (2006).   DOI   ScienceOn
11 Y. Kuno, M. Kojima, S. Ando. and H. Nakagami, J. Control. Release, 105, 16 (2005).   DOI   ScienceOn
12 J. Fukami, E. Yonemochi, Y. Yoshihashi, and K. Terada, Int. J. Pharm., 310, 101 (2006).   DOI   ScienceOn
13 Y. Ozeki, M. Ando, Y. Watanabe, and K. Danjo, J. Control. Release, 95, 51 (2004).   DOI   ScienceOn
14 H. Jua'rez, G. Rico, and L. Villafuert, Int J. Pharm., 216, 115 (2001).   DOI   ScienceOn
15 J. Varshosaz and Z. Dehghan, Eur. J. Pharm. Biopharm., 54, 135 (2002)   DOI   ScienceOn
16 P. Mura, M. T. Fauucci, A. Manderioli, G. Bramanti, and L. Ceccarelli, J. Pharmaceut. Biomed., 18, 151 (1998).   DOI   ScienceOn
17 H. Ma, G. P. Andrews, D. S. Jones, and G. M. Walker, Chem. Eng. J., in press (2010).
18 A. C. Williams, P. Timmins, M. Lu, and R. T. Forbes, Eur. J. Pharm. Sci., 26, 288 (2005).   DOI   ScienceOn
19 R. Guchardi, M. Frei, E. John, and J. S. Kaerger, Int. J. Pharm., 348, 10 (2008).   DOI   ScienceOn
20 A. Mehrotra, M. Llusa, A. Faqih, M. Levin, and F. J. Muzzio, Int. J. Pharm., 336, 284 (2007).   DOI   ScienceOn
21 N. Dapier-Beche, J. Fanni, and M. Parmentier, J. Dairy. Sci., 82, 2558 (1999).   DOI   ScienceOn
22 Y. Takahashi, C. Takeda, I. Seto, G. Kawano, and Y. Machida, Int. J. Pharm., 343, 220 (2007).   DOI   ScienceOn
23 S. I. Abdel-Rahman, M. G. Mahrous, and M. El-Badry, Saudi Pharm. Journal, 17, 283 (2009).   DOI   ScienceOn
24 C. Bin, S. C. Joshi, and Y. C. Lam, Carbohydr. Polym., 75, 282 (2009) .   DOI   ScienceOn
25 J. H. Park, J. Ku, S. I. Ahn, J. H. Lee, Y. T. Kim, D. S. Kim, W. Kim, J. M. Rhee, and G. Khang, Tissue Eng. Regen. Med., 5, 729 (2008).
26 S. Miyazaki, N. Kawasaki, T. Nakamura, M. Iwatsu, T. Hayashi, W. -M. Hou, and D. Attwood, Int. J. Pharm., 204, 127 (2000).   DOI   ScienceOn
27 K. Zuurman, K. V. V. Maarschalk, and G. K. Bolhuis, Int. J. Pharm., 179,107 (1999).   DOI   ScienceOn
28 E. Fukui, N. Miyamura, and M. Kobayashi, Int. J. Pharm., 216, 137 (2001).   DOI   ScienceOn
29 Y. Cui, S. S. Kim, and E. S. Park, J. Kor. Pharm. Sci., 32, 95 (2002).
30 A. C. Shah and N. J. Britten, J. Control. Release, 14, 179 (1990).   DOI   ScienceOn